Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Report on the community-acquired pneumonia drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics -- levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.

9 Dec 2009

Research article addresses the relationship between PEG and GER

Gastroesophageal reflux (GER) is a common problem in mechanically ventilated patients and contributes to the development of esophageal mucosal injury and even erosive esophagitis. The relationship between percutaneous endoscopic gastrostomy (PEG) and subsequent development of GER is complex and not well understood.

9 Dec 2009

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases.

9 Dec 2009

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376).

9 Dec 2009

Severe pandemic scenario can impact blood supplies

A German research team has examined data on supply and demand for blood transfusions against a computer simulation of an influenza pandemic, and discovered that a severe pandemic scenario could quickly lead to a deficit of up to 96,000 red blood cell (RBC) transfusion units in Germany alone, creating potentially fatal outcomes. Their study is published today in the journal TRANSFUSION.

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Macomb County Health Department opens new H1N1 influenza immunization clinics

Sfter holding more than a dozen H1N1 influenza immunization clinics this fall targeting people in high-risk groups, the Macomb County Health Department announced today that it is opening its upcoming clinics to everyone 6 months of age and older.

9 Dec 2009

Bird influenza viruses have a variety of strategies to cross the species barrier

The 2009 H1N1 influenza virus used a new strategy to cross from birds into humans, a warning that it has more than one trick up its sleeve to jump the species barrier and become virulent.

9 Dec 2009

Opinions: ARV access; global health promotion; climate change; under-nutrition; Ethiopia

In an Intellectual Property Watch column, Daniele Dionisio, of the Italian Network for International Fight against AIDS, examines how trade rules and policy directions by governments and institutions may help to improve countries' access to antiretrovirals.

8 Dec 2009

Swine flu news round-up

The German government is looking to sell over 2 million leftover doses of the H1N1 (swine flu) vaccine, the country's health minister said Monday, Agence France-Presse reports. "A health ministry senior official in the state of Thuringia, Hartmut Schubert, said that the vaccines could even be donated and that there had been requests from Afghanistan and Eastern European countries including Ukraine," the news service adds (12/7).

8 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

New room temperature-based liquid formulation for storage of tissues and cells

Biomatrica, the leader in room temperature biological sample stabilization, today announced the release of DNAgard(TM), the first room temperature-based liquid formulation for stabilization and storage of tissues and cells. The new DNAgard product adds to Biomatrica's portfolio of solutions for room-temperature storage, archiving, stabilization and transportation of biological samples.

8 Dec 2009

New iPhone application to help find the top doctor

Have no fear during holiday travel this year — if you’re in a strange city, feel flu-like symptoms coming on and want to find a doctor, there’s a new iPhone App that will find one for you. The i Need a Doctor™ (www.ineedadoc.net) app is a joint venture between The Paladin Group LLC, the app developer, and two of the most respected doctor-rating services in the United States — the health care research organization Castle Connolly Medical Ltd. (www.castleconnolly.com) and the physician rating site DrScore (www.drscore.com).

8 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology’s annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

8 Dec 2009

Tips for avoiding holiday weight gain

With obesity rates at all time highs, and the season of food, comfort and overindulgence right around the corner, the fear of weight gain is very real for most people. Keep off those pesky holiday pounds by upping fitness this December, and get a jump start on that New Year's resolution with the help of some guidance from Life123.com, a leading source of expert advice.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Report on the community-acquired pneumonia drug market

Research article addresses the relationship between PEG and GER

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Memgen announces positive clinical data of ISF35 with chemotherapy

Severe pandemic scenario can impact blood supplies

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

TMZ and small molecule combination appears to lower tumor resistance

Macomb County Health Department opens new H1N1 influenza immunization clinics

Bird influenza viruses have a variety of strategies to cross the species barrier

Opinions: ARV access; global health promotion; climate change; under-nutrition; Ethiopia

Swine flu news round-up

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

New room temperature-based liquid formulation for storage of tissues and cells

New iPhone application to help find the top doctor

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

New data provide comprehensive review of emerging role of small airways in asthma management

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Tips for avoiding holiday weight gain

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in